NeuroSense Therapeutics Statistics
Total Valuation
NRSN has a market cap or net worth of $21.49 million. The enterprise value is $19.27 million.
| Market Cap | 21.49M |
| Enterprise Value | 19.27M |
Important Dates
The last earnings date was Friday, April 5, 2024, before market open.
| Earnings Date | Apr 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NRSN has 17.33 million shares outstanding. The number of shares has increased by 8.34% in one year.
| Shares Outstanding | 17.33M |
| Shares Change (YoY) | +8.34% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 28.56% |
| Owned by Institutions (%) | 1.03% |
| Float | 11.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.84
| Current Ratio | 0.84 |
| Quick Ratio | 0.83 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.11 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -207.30% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$626,667 |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.57% in the last 52 weeks. The beta is 1.56, so NRSN's price volatility has been higher than the market average.
| Beta (1Y) | 1.56 |
| 52-Week Price Change | -40.57% |
| 50-Day Moving Average | 1.64 |
| 200-Day Moving Average | 1.06 |
| Relative Strength Index (RSI) | 34.18 |
| Average Volume (30 Days) | 314,114 |
Short Selling Information
The latest short interest is 88,412, so 0.51% of the outstanding shares have been sold short.
| Short Interest | 88,412 |
| Short Previous Month | 63,716 |
| Short % of Shares Out | 0.51% |
| Short % of Float | 0.79% |
| Short Ratio (days to cover) | 0.44 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -13.30M |
| Pretax Income | -11.28M |
| Net Income | -11.28M |
| EBITDA | -8.97M |
| EBIT | -9.07M |
| Earnings Per Share (EPS) | -$0.83 |
Balance Sheet
The company has $2.64 million in cash and $73,000 in debt, giving a net cash position of $2.57 million or $0.15 per share.
| Cash & Cash Equivalents | 2.64M |
| Total Debt | 73,000 |
| Net Cash | 2.57M |
| Net Cash Per Share | $0.15 |
| Equity / Book Value | -1.87M |
| Book Value Per Share | -0.11 |
| Working Capital | -543,000 |
Cash Flow
In the last 12 months, operating cash flow was -$8.45 million and capital expenditures -$29,000, giving a free cash flow of -$8.48 million.
| Operating Cash Flow | -8.45M |
| Capital Expenditures | -29,000 |
| Free Cash Flow | -8.48M |
| FCF Per Share | -$0.68 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NRSN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.34% |
| Shareholder Yield | -8.34% |
| Earnings Yield | -51.65% |
| FCF Yield | -38.83% |
Analyst Forecast
The average price target for NRSN is $7.50, which is 490.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.50 |
| Price Target Difference | 490.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |